

AUDITED FINANCIAL RESULTS FOR THE QUARTER / YEAR ENDED ON 31ST DECEMBER, 2011

Sr. No.	Particulars	Independent Financials						Consolidated Financials					
		3 Month Ended			12 Month Ended			3 Month Ended			12 Month Ended		
		31.12.2011	31.12.2010	30.09.2011	31.12.2011	31.12.2010	31.12.2011	31.12.2010	30.09.2011	31.12.2011	31.12.2010	31.12.2011	31.12.2010
		(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)	(Unaudited)	(Audited)	(Audited)	(Audited)	(Audited)
1	Net Sales/Income from Operations	11499.94	11108.43	13321.36	49562.83	43282.78	42054.50	41336.27	41195.30	164066.00	151811.50		
2	Other Incomes	(2.00)	8.25	6.13	23.70	40.04	19.90	14.27	15.00	72.00	116.10		
3	Total Income (1+2)	11497.94	11116.68	13327.49	49586.53	43322.81	42074.40	41350.54	41210.30	164138.00	151927.60		
4	Expenditure												
	a) (Increase) / Decrease in Stock in trade & work in progress	110.65	333.12	(399.71)	(567.49)	165.82	269.10	(1048.58)	(2479.40)	(1525.80)	(2734.20)		
	b) Consumption of Raw Materials	1039.51	5270.20	5122.14	19952.52	21348.58	2939.10	7426.04	7139.60	26724.60	37538.90		
	c) Purchase of Finished goods	1861.98	230.29	2554.23	5141.99	425.72	18236.80	14383.24	14076.50	55923.30	39065.90		
	d) Employees Cost	902.75	900.64	848.42	3539.51	3109.20	3799.50	4362.00	1937.00	11492.70	11730.60		
	e) Depreciation/Amortization	208.14	255.58	212.51	921.16	937.61	464.70	1394.49	432.70	1860.10	2836.00		
	f) Other Expenditure	1896.47	2401.14	2869.16	9324.29	8021.04	12154.70	10323.54	11352.20	41889.80	34882.60		
	Total Expenditure	6019.50	9390.98	11206.75	38311.97	34007.96	37863.90	36840.73	32458.60	136364.70	123319.80		
5	Interest (Net)	5386.70	770.56	993.51	7718.83	2930.54	5905.40	800.21	1047.70	8354.30	3054.60		
6	Exceptional items	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00		
7	Profit (+) / Loss (-) from Ordinary Activities before tax (3) - (4+5+6)	91.74	955.14	1127.23	3555.73	6384.30	(1694.90)	3709.60	7704.00	19419.00	25553.20		
8	Tax expense	129.01	926.81	212.26	1019.53	1962.52	1735.90	1236.04	638.30	2827.70	2482.20		
9	Net Profit (+) / Loss (-) from Ordinary Activities after tax (7-8)	(37.26)	28.33	914.97	2536.21	4421.79	(3430.80)	2473.56	7065.70	16591.30	23071.00		
10	Extra-Ordinary Items (net of tax expense)	(3097.50)	172.50	(3206.25)	(6300.00)	1368.75	(3097.50)	172.50	(3206.30)	(6300.00)	1368.80		
11	Net Profit (+) / Loss (-) for the period (9 - 10)	(3134.76)	200.83	(2291.28)	(3763.79)	5790.54	(6528.30)	2646.06	3859.40	10291.30	24439.80		
12	Paid-up equity share capital (Nominal Value - Rs. 10/- each)	3406.67	3406.67	3406.67	3406.67	3406.67	3407.67	3407.67	3407.67	3407.67	3406.67		
13	Reserves excluding Revaluation reserves as per balance sheet of previous accounting year	-	-	-	61102.86	64405.95	-	-	-	-	-		
14	Earning Per Share (EPS)												
	(a) EPS before Extra-Ordinary items for the period, for the year to date and for the previous year (not to be annualized) (Rs.)												
	Basic	(0.11)	0.08	2.69	7.44	12.98	(10.07)	7.26	20.74	48.70	67.72		
	Diluted	(0.09)	0.07	2.26	6.25	11.02	(8.45)	6.16	17.42	40.89	57.48		
	b) EPS after Extra-Ordinary items for the period, for the year to date and for the previous year (not to be annualized) (Rs.)												
	Basic	(9.20)	0.59	(6.73)	(11.05)	17.00	(19.16)	7.77	11.33	30.21	71.74		
	Diluted	(7.73)	0.50	(5.65)	(9.28)	14.43	(16.09)	6.59	9.52	25.36	60.89		
15	Public Shareholding												
	a) Number of equity shares	4426667	4426667	4426667	4426667	4426667	4426667	4426667	4426667	4426667	4426667		
	b) Percentage of Shareholding	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%	12.99%		
16	Promoter and Promoter Group Shareholding :												
	a) Pledged/Encumbered												
	- Number of shares	27846050	24186865	24932050	27846050	24186865	-	-	-	-	-		
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	93.95%	81.60%	84.12%	93.95%	81.60%	-	-	-	-	-		
	- Percentage of shares (as a % of the total share capital of the Company)	81.74%	71.00%	73.19%	81.74%	71.00%	-	-	-	-	-		
	b) Non-encumbered												
	- Number of shares	1793950	5453135	4707950	1793950	5453135	-	-	-	-	-		
	- Percentage of Shares (as a % of total shareholding of promoter and promoter group)	6.05%	18.40%	15.88%	6.05%	18.40%	-	-	-	-	-		
	- Percentage of shares (as a % of the total share capital of the Company)	5.27%	16.01%	13.82%	5.27%	16.01%	-	-	-	-	-		



Disclosure of Balance Sheet Items as per Clause 41 (V) (h) of the Listing Agreement for the year Ended 31-Dec-2011

Sr. No	Particulars	Independent Financials		Consolidated Financials	
		As on		As on	
		31.12.2011 Audited	31.12.2010 Audited	31.12.2011 Audited	31.12.2010 Audited
1	SHAREHOLDERS' FUNDS:	66509.52	69923.70	136486.10	107106.50
a	- Capital				
	i) Equity Share Capital	3406.67	3406.70	3406.67	3406.70
	ii) Share Warrant application Money	2000.00	0.00	2000.00	0.00
b	- Reserves and Surplus	61102.86	66517.00	131079.43	103693.80
2	Deferred Tax Liability (NET)	1596.93	1551.40	(1342.70)	(2582.90)
3	LOAN FUNDS	89419.53	58105.80	109146.10	58105.70
4	FIXED ASSETS	13287.25	13932.50	84640.00	66643.30
5	INVESTMENTS	80655.91	77557.10	19892.40	19692.40
6	CURRENT ASSETS, LOANS AND ADVANCES	69534.95	43337.00	149860.80	93805.30
a	- Inventories	2232.81	1595.70	18203.60	15626.30
b	- Sundry Debtors	59605.80	35288.90	97058.20	63712.10
c	- Cash and Bank balances	2753.24	1243.20	11040.40	4053.80
d	- Other current assets				
e	- Loans and Advances	4943.11	5209.30	23558.60	10413.10
7	Less: Current Liabilities and Provisions	6003.19	5393.20	10314.70	17999.50
a	- Liabilities	3089.61	2464.70	7371.40	14774.20
b	- Provisions	2913.58	2928.50	2943.30	3225.30
8	MISCELLANEOUS EXPENDITURE (NOT WRITTEN OFF OR ADJUSTED)	50.07	147.50	211.00	281.80
9	PROFIT AND LOSS ACCOUNT	-	-	-	-
10	TOTAL	-	-	-	-

1. The above audited financial results for the quarter and year ended on 31st December, 2011 were approved at the meeting of the Board of Directors held on 29th Feb, 2011, after being approved and recommended by the Audit Committee.

2. The Company is engaged in a single segment viz. Pharmaceuticals which is governed by the same set of risks and returns, therefore the Accounting Standard (AS-17) on "Segment Reporting" issued by ICAI, is not applicable.

3. The EPS has been computed in accordance with the accounting standards (AS-20) issued by the ICAI

4. Figures of the previous quarter / year wherever necessary have been regrouped and reclassified to confirm to those of the current quarter / Year .

5. The cost of Packing materials has been included in other expenditure, whereas Director's remuneration has been included in the employees cost.

6. The consolidated financial results comprise results of its wholly owned subsidiary Plethico International Ltd and Plethico Global Holdings B.V., Netherlands having different step-down subsidiaries particularly Plethico US Holding KFT Hungary, Natrol Inc., USA. and Natrol Global UAE., The financial results of subsidiary companies have been regrouped and / or rearranged wherever necessary due to indian GAPP audit conducted.

7. Extra-ordinary items is related to unrealized exchange loss of Rs. 6300.00 Lacs arising on account of restatement of outstanding Foreign Currency Convertible Bonds (FCCB) at the rate prevailing at the end of year.

8. Provision on account of premium payable on redemption of FCCB amounting to Rs.5400.22 Lacs for the year ended on 31st December, 2011 has been provided out of Share Premium Reserve Rs 1650.74 & Profit & Loss account Rs 3749.48.

9. Details of Investors complaints for the quarter ended: Unresolved at the beginning of the quarter - Nil, Received during the quarter - 3, Disposed off during the quarter - 3, Unresolved at the end of the quarter - Nil.

10. The Figures for the last quarter of the current and the previous years are the balancing figures between audited figures for the full financial years and the unaudited published year-to-date figures for nine months for respective years.

Date : 29th February, 2012
Place : Indore



For PLETHICO PHARMACEUTICALS LIMITED

SHASHIKANT PATEL
CHAIRMAN CUM MANAGING DIRECTOR